OuvertAccord de coopérationNon ouvert aux organisations étrangères

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)

National Institutes of Health · Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847)

Publié 8 juin 2026 · Clôture demain

En clair

Résumé pas encore disponible en français ; affiché en anglais.

The U.S. National Institutes of Health funds clinical centers to conduct trials testing anti-obesity medication treatment strategies for children and adolescents, examining optimal timing, dosing, and adjunct therapies while monitoring development and mental health. Grants up to 1 million US dollars are available to U.S.-based organisations only, with applications due by 9 October 2026.

Un résumé généré du texte du bailleur ; la formulation originale figure ci-dessous.

Résumé

Texte original du bailleur (anglais)

This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols…

Extrait de la page du bailleur. Le texte intégral, les annexes et les formulaires se trouvent dans l'appel original.

Qui peut candidater

  • ONG / société civile
  • Établissement universitaire ou de recherche
  • Entreprise privée
  • Organisme public
  • Organisation communautaire

Éligibilité et conditions

Afficher le texte d'éligibilité de la source · Texte original du bailleur (anglais)

Applicant types: Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); City or township governments; Public housing authorities/Indian housing authorities; Independent school districts; Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Small businesses; Special district governments; For profit organizations other than small businesses; Private institutions of higher education; County governments

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Thèmes